70338-47-5

Upstream product

• 39062-69-6 4-benzyloxy-3-trifluoromethyl-nitrobenzene 
• 1548-61-4 4-nitro-2-(trifluoromethyl)phenol 
• 100-39-0 benzyl bromide 
• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 
• 100-51-6 benzyl alcohol 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 

Downstream Products

• 82578-53-8 5-Benzyloxy-N-(4-benzyloxy-3-trifluormethylphenyl)anthranilsaeure 
• 39062-71-0 4'-Benzyloxy-flufenaminsaeure 
• 231278-27-6 (6-iodo-(4-benzyloxy-3-trifluoromethyl-phenyl)-quinazolin-4-yl)amine 
• 231278-32-3 5-(4-(4-benzyloxy-3-trifluoromethylphenylamino)-quinazolin-6-yl)-furan-2-carbaldehyde 
• 39062-72-1 4'-Hydroxyflufenaminsaeure 
• 76874-95-8 5,4'-Dihydroxyflufenaminsaeure 

Relevant academic research and scientific papers

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

A pharmaceutical formulation comprising the compound of formula

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work.

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Synthesis and properties of nuclear hydroxylated derivatives of flufenamic acid and etofenamate

Synthesis of six nuclear hydroxylated derivatives of flufenamic acid and etofenamate (5-OH-, 4'-OH and 5,4'-(OH2) on a preparative scale is described. All compounds show low toxicity, by only weak anti-inflammatory activity in the rat paw kaolin edema test as compared to 2-(2-hydroxyethoxy)ethyl-N-(α,α,α-trifluoro-m-tolyl)-anthranilate (etofenamate, active substance of Rheumon Gel).

Cycloalkanecarboxanilide derivative herbicides

Certain cycloalkanecarboxanilide derivatives are useful as herbicides.